PET Imaging for Cardiac Toxicity
What You Need to Know Before You Apply
What is the purpose of this trial?
This study is a single center, phase 1 clinical imaging study designed to assess the role of 68Ga-Galmydar Positron Emission Tomography (PET) imaging for detection of cardiotoxicity in human subjects with breast cancer or lymphoma undergoing treatment with anthracycline for cancer therapy.
Who Is on the Research Team?
Pamela K Woodard, MD
Principal Investigator
Washington University School of Medicine
Are You a Good Fit for This Trial?
This trial is for people with breast cancer or lymphoma who are receiving anthracycline chemotherapy. Participants should be able to undergo PET/MRI scans and not have conditions that would make imaging unsafe.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- 18F-FDG
- 68Ga-Galmydar
Trial Overview
The study tests a new imaging method using 68Ga-Galmydar in PET/MRI scans, comparing it to standard 18F-FDG PET, to see if it can better detect heart damage caused by chemotherapy.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Lymphoma patients: baseline prior to the start of chemotherapy treatment, after the patient has had at least 250 mg/m\^2 of anthracycline (after the 5th cycle \& before the 6th cycle of anthracycline in Non-Hodgkin lymphoma or after the 5th cycle (10 treatments) in Hodgkin lymphoma, 1-3 weeks after the 5th cycle of anthracycline), and 12-months (+/- 1 month) post-treatment Breast patients: baseline prior to the start of all chemotherapy treatments, baseline after Paclitaxel and prior to the start of AC (Adriamycin \& Cyclophosphamide) for patients treated with the Keynote-522 regimen, 1-2 weeks after the last dose (4 cycles) of AC, and 12-months (+/- 1 month) post-treatment Echocardiography will be performed at all PET imaging sessions \& at 6- and 9-months post-chemotherapy A subset of 3 breast \& 3 lymphoma patients will undergo 18F-FDG PET/MRI. Patients undergoing 18F-FDG PET/MRI will stay overnight \& will be imaged with 18F-FDG in the morning on day 2 under fasting conditions
Find a Clinic Near You
Who Is Running the Clinical Trial?
Washington University School of Medicine
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.